Renascience, The Current Fiscal Year Net Income Turns to Profit, Exceeds Expectations

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Dec 6, 2024 3:30 pm JST Revision

4889 Renascience Inc. 【J-GAAP】

Guidance Update Report

Renascience Inc. <4889> [TSE Growth] announced a performance revision after the market closed on December 6th (15:30). The net income (non-consolidated) for the fiscal year ending March 2025 has been revised upward from an expected loss of 91 million yen to a profit of 46 million yen (compared to a loss of 258 million yen in the previous period), turning to a profit. However, the full-year ordinary profit/loss has been revised downward from an expected loss of 257 million yen to a loss of 267 million yen (compared to a loss of 251 million yen in the previous period), indicating an expansion in the loss margin.

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (second half) net income has been revised upward from an expected loss of 19 million yen to a profit of 118 million yen (compared to a loss of 163 million yen in the same period of the previous year), turning to a profit.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	50	-167	-165	-19	-1.5	0	Nov 14, 2024	J-GAAP
Oct - Mar, 2024 New	72	-177	-175	118	9.3	0	Dec 6, 2024	J-GAAP
Revision Rate	+44.0%	-6.0%	-6.1%	－	－

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	105	-257	-257	-91	-7.2	0	Jul 3, 2024	J-GAAP
Mar, 2025 New	127	-267	-267	46	3.6	0	Dec 6, 2024	J-GAAP
Revision Rate	+21.0%	-3.9%	-3.9%	－	－

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	74	-158	-157	-163	-12.8	0	May 9, 2024	J-GAAP
Oct - Mar, 2024 Guidance	72	-177	-175	118	9.3	0	Dec 6, 2024	J-GAAP
YoY	-2.7%	-12.0%	-11.5%	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	100	-333	-333	-335	-26.4	0	May 11, 2023	J-GAAP
Mar, 2024	194	-252	-251	-258	-20.3	0	May 9, 2024	J-GAAP
Mar, 2025 Guidance	127	-267	-267	46	3.6	0	Dec 6, 2024	J-GAAP
YoY	-34.5%	-6.0%	-6.4%	－	－